What is the recommended dose of Filgastrim (Granulocyte-Colony Stimulating Factor, G-CSF)?

From the Guidelines

The recommended dose of Filgrastim is 5 micrograms per kilogram of body weight per day for all clinical settings other than peripheral blood progenitor cell (PBPC) mobilization, where a dose of 10 micrograms per kilogram per day may be preferable, as stated in the American Society of Clinical Oncology clinical practice guideline update 1.

Key Considerations

• The dose of Filgrastim should be individualized based on the patient's weight and clinical condition.
• The medication should be administered subcutaneously, and the preferred route of administration is subcutaneous injection.
• Filgrastim should be started 1 to 3 days after administration of myelotoxic chemotherapy, and continued until the absolute neutrophil count (ANC) reaches 2 to 3 x 10^9/L.
• For PBPC mobilization, Filgrastim should be started 4 days before the first leukapheresis procedure and continued until the last leukapheresis.

Clinical Context

• Filgrastim is used to reduce the incidence of infection, in the setting of chemotherapy-induced neutropenia.
• The medication works by stimulating the bone marrow to produce neutrophils, which helps to prevent infections in patients with low white blood cell counts.
• Patients should be monitored for potential side effects, including bone pain, which can be managed with analgesics.
• Dose adjustments may be necessary based on ANC monitoring and individual patient response, as recommended by the American Society of Clinical Oncology 1 and other studies 1.

From the FDA Drug Label

The recommended dosage of ZARXIO following bone marrow transplantation (BMT) is 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. The recommended dosage of ZARXIO for the mobilization of autologous peripheral blood progenitor cells (PBPC) is 10 mcg/kg/day given by subcutaneous injection. The recommended starting dosage in patients with Congenital Neutropenia is 6 mcg/kg as a twice daily subcutaneous injection and the recommended starting dosage in patients with Idiopathic or Cyclic Neutropenia is 5 mcg/kg as a single daily subcutaneous injection. The recommended dosage of ZARXIO is 10 mcg/kg as a single daily subcutaneous injection for patients exposed to myelosuppressive doses of radiation.

The recommended dose of Filgastrim (Granulocyte-Colony Stimulating Factor, G-CSF) varies depending on the patient's condition:

• Bone Marrow Transplantation: 10 mcg/kg/day intravenously
• Autologous Peripheral Blood Progenitor Cell Collection and Therapy: 10 mcg/kg/day subcutaneously
• Severe Chronic Neutropenia:
  • Congenital Neutropenia: 6 mcg/kg twice daily subcutaneously
  • Idiopathic or Cyclic Neutropenia: 5 mcg/kg daily subcutaneously
• Acute Radiation Syndrome: 10 mcg/kg daily subcutaneously 2

From the Research

Filgastrim Dose

The recommended dose of Filgastrim, also known as Granulocyte-Colony Stimulating Factor (G-CSF), is not explicitly stated in the provided studies. However, the following information can be gathered:

• G-CSF is used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases 3.
• The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation 4.
• G-CSF influences the survival, proliferation, and differentiation of all cells in the neutrophil lineage, from haemopoietic stem cell through to mature neutrophil 5.
• The mechanism of action of G-CSF involves binding to its receptor (G-CSFR) and stimulating neutrophils mobilization 6.
• The use of G-CSF in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases, according to the Japan Society of Clinical Oncology guidelines 7.

Key Points

• G-CSF is used to treat various types of neutropenia and to mobilize peripheral hematopoietic progenitor cells for stem cell transplantation.
• The mechanism of action of G-CSF involves binding to its receptor and stimulating neutrophils mobilization.
• The use of G-CSF in patients with febrile neutropenia is not routinely recommended except in high-risk cases.
• The recommended dose of Filgastrim is not explicitly stated in the provided studies, and further research is needed to determine the optimal dosage.

Dosage Information

• Unfortunately, there is no specific information on the recommended dose of Filgastrim in the provided studies.
• It is essential to consult the prescribing information or a healthcare professional for guidance on the appropriate dosage of Filgastrim for specific indications.